Dr. Khosravi begins with neuromuscular manifestations, noting these have been referenced throughout the discussion. Symptoms include muscle spasms and cramps in the acral areas, generalized weakness, fatigue, and brain fogginess, with severe cases presenting as laryngospasm or seizures. She explains that many of these symptoms stem from hypocalcemia that is not fully corrected or from calcium fluctuations. On conventional calcium and active vitamin D therapy, clinicians must accept a lower serum calcium target to avoid hypercalciuria, but this leaves patients vulnerable when they are ill, under stress, or overtreated — all situations that can destabilize calcium levels. Correcting magnesium, dividing calcium doses, and adding thiazide diuretics when needed are key management strategies to improve calcium stability.

On the skeletal side, PTH deficiency leads to low bone turnover and paradoxically elevated DXA-measured bone density. Dr. Khosravi recommends DXA with vertebral fracture assessment (VFA) where available, particularly in non-surgical patients who carry an elevated risk of vertebral fractures — many of which are asymptomatic. Bone turnover markers are expected to be low on conventional therapy and have limited management utility, though they shift meaningfully in the first six months of PTH replacement.

Regarding skeletal management, antiresorptive agents are generally not the preferred strategy given the already suppressed bone turnover, though PTH analogs such as teriparatide are more rational. When PTH replacement is initiated, bone density may transiently decrease before reaching a more normal equilibrium. In patients who already have low bone density and require antiresorptives, clinicians must monitor calcium closely, as further suppression of bone turnover can precipitate hypocalcemia requiring upward titration of PTH replacement — a genuine clinical catch-22. She notes that robust data on skeletal management in this setting remain limited, and current guidance is largely based on mechanism of action. Dr. Cusano adds that the elevated baseline bone density in many patients, particularly postmenopausal women, may lead clinicians to underestimate fracture risk.

In the next episode, "Renal Complications of Chronic Hypoparathyroidism," Dr. Ferenczi provides a detailed examination of nephrolithiasis, nephrocalcinosis, and CKD in hypoparathyroidism, explaining how both the disease itself and conventional therapy contribute to progressive kidney damage.